Actionnariat et activité des initiés pour REGENXBIO Inc. (RGNX): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $7.98 |
| Capitalisation | $413M |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-09-01 | Malzahn Craig | F-InKind | 234 | $2K |
| 2026-09-01 | Chan Mitchell | F-InKind | 4,902 | $46K |
| 2026-08-27 | Ciongoli Gregory Austin | P-Purchase | 53,407 | $500K |
| 2026-08-25 | Ciongoli Gregory Austin | A-Award | 69,609 | $620K |
| 2026-08-26 | Ciongoli Gregory Austin | P-Purchase | 49,196 | $450K |
| 2026-08-25 | Ciongoli Gregory Austin | A-Award | 15,432 | |
| 2026-08-25 | Ciongoli Gregory Austin | |||
| 2026-08-01 | PAKOLA STEVE | F-InKind | 7,468 | $72K |
| 2026-08-01 | Christmas Patrick J. | F-InKind | 4,699 | $46K |
| 2026-06-30 | Simpson Curran | A-Award | 1,453 | $15K |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $24.8M | $46.7M | $75.6M | $69.5M | $338.4M | $345.2M | $97.0M | $34.5M | $57.5M | $34.5M |
| Placements à Court Terme | $64.7M | $114.1M | $244.2M | $226.7M | $137.3M | $112.2M | $267.7M | $240.7M | $177.2M | $195.6M |
| Créances | $1.0M | $473000 | $8.6M | $38.1M | $43.0M | $32.4M | $30.3M | $26.3M | $21.6M | $27.4M |
| Stocks | $1.8M | $5.3M | $5.7M | 0 | $10.5M | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $93.4M | $168.0M | $337.9M | $345.0M | $531.2M | $518.8M | $416.0M | $335.0M | $278.0M | $281.3M |
| Immobilisations Corporelles | $9.3M | $14.0M | $28.7M | $39.1M | $120.3M | $192.5M | $206.8M | $192.6M | $171.3M | $152.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $172.7M | $198.7M | $543.8M | $497.9M | $708.2M | $1.11B | $833.3M | $574.0M | $466.0M | $453.0M |
| Dettes Fournisseurs | $1.5M | $4.8M | $4.4M | $6.4M | $10.6M | $11.4M | $27.2M | $22.8M | $22.8M | $21.4M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $47.9M |
| Passifs Courants | $9.7M | $14.4M | $22.2M | $33.7M | $81.4M | $130.5M | $130.4M | $130.3M | $103.2M | $118.1M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $147.4M |
| Passifs Totaux | $11.0M | $15.6M | $35.0M | $47.7M | $330.4M | $349.6M | $317.1M | $262.2M | $206.3M | $350.3M |
| Réserves | -$114.6M | -$187.8M | -$83.0M | -$177.8M | -$289.1M | -$161.2M | -$441.6M | -$705.0M | -$932.1M | -$1.13B |
| Capitaux Propres | $161.7M | $183.0M | $508.8M | $450.2M | $377.8M | $764.3M | $516.2M | $311.7M | $259.7M | $102.7M |
| Dette Totale | 0 | 0 | $5.9M | $11.3M | $72.7M | $86.7M | $94.8M | $89.3M | $82.0M | $260.5M |
| Dette Nette | -$89.6M | -$160.8M | -$313.9M | -$284.9M | -$403.1M | -$370.8M | -$269.8M | -$186.0M | -$152.7M | $30.4M |
| Fonds de Roulement | $83.7M | $153.6M | $315.7M | $311.4M | $449.8M | $388.4M | $285.5M | $204.7M | $174.8M | $163.2M |
Santé financière
| Dette / Capitaux propres | 0.96 |
| Ratio de liquidité | 2.86 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.57 |
Rentabilité
| Rentabilité des capitaux propres | -220.07% |
| Rentabilité du capital investi | -52.72% |
| Rentabilité des actifs | -50.81% |
| Marge brute | 54.22% |
| Marge opérationnelle | -94.08% |
| Marge nette | -112.58% |
Entreprises liées: ABSI · CRVS · FDMT · GOSS · KALV · MLTX · OLMA
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de RGNX: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions